1. Introduction {#sec1}
===============

Alzheimer\'s disease (AD) is the most common form of dementia among the elderly population \[[@B1], [@B2]\]. A major hallmark of AD is the abnormal processing and accumulation of neurite plaques containing amyloid *β*-peptide (A*β*) in the brain \[[@B3], [@B4]\]. Amyloid precursor protein (APP) is mainly cleaved by the *α*-secretase enzyme ([Figure 1](#fig1){ref-type="fig"}), producing the secretory form of amyloid precursor protein (sAPP; *β*-amyloid (A*β*) 17--42), which is soluble and nontoxic \[[@B5]\]. However, when APP is cleaved by *β*- and *γ*-secretase enzymes \[[@B6]\], it leads to the formation of A*β*1--40 and A*β*1--42, which are insoluble unlike sAPP, and results in the accumulation of amyloid plaques \[[@B7]\]. In the production of A*β*1--42, the A*β*1--42/A*β*1--40 ratio is associated with the amount of insoluble A*β* aggregation \[[@B8]\]. On the other hand, the abnormal hyperphosphorylation of tau results in insoluble fibrils and neurofibillary tangels in the brain \[[@B9], [@B10]\]. Thus, an understanding of the pathological processes of APP and tau in AD is a critical therapeutic target in preventing or delaying AD in humans \[[@B11]--[@B13]\]. Here, we review the role of protein kinase C (PKC) in A*β* production and clearance through *α*-secretase or A*β*-degrading enzyme activity. Among several PKCs, we focus on the role of PKC*ε* in A*β* levels because several recent findings have demonstrated that the activation or overexpression of PKC*ε* promotes the A*β* degradation activity of endothelin converting enzyme type 1 (ECE-1) \[[@B14], [@B15]\].

2. PKC and A***β*** Plaques {#sec2}
===========================

PKC is a phospholipid-dependent serine/threonine kinase and consists of at least 12 isoenzymes \[[@B16], [@B17]\]. PKCs can be classified into three subfamilies based on their protein structure and second messenger requirements: conventional (or classical), novel, and atypical. Conventional PKCs contain the *α*, *β1*, *β2*, and *γ* isoforms and require Ca^2+^, diacylglycerol (DAG), and a phospholipid such as phosphatidylcholine for activation. Novel PKCs include the *δ*, *ε*, *η*, *θ*, and *μ* isoforms and require DAG or phospholipids but do not require Ca^2+^ for activation. On the other hand, atypical PKCs consisting of protein kinase *ζ*, *ι*, and *λ* isoforms do not require either Ca^2+^ or diacylglycerol for activation \[[@B18]\].

Numerous studies have suggested that phorbol 12-myristate 13-acetate (PMA), a nonspecific PKC activator, is capable of lowering secreted A*β* levels in neurons \[[@B19]--[@B22]\]. Based on these results, several studies have attempted to identify precisely which PKC isozyme actually regulates APP processing. The overexpression of PKC*α* or PKC*ε*, but not PKC*θ*, has been shown to induce APP secretion from cells \[[@B23]\]. Interestingly, specific inhibition of either PKC*α* or PKC*θ* in CHO cells expressing APP695 was associated with a loss of PMA-mediated APP secretion \[[@B24]\]. In addition, experiments with a dominant negative fragment of PKC*ε* reduced phorbol ester-induced secretion of sAPP*α* \[[@B15], [@B25]\]. However, even though intraparenchymal administration of phorbol esters reduces A*β* levels and decreases amyloid plaque density in mice expressing an amyloidogenic variant of human APP, *α*-secretase activity is not increased in the brain \[[@B26]\]. This raises the possibility that PKC reduces A*β* levels *in vivo* by another mechanism.

3. A***β*** Clearance and Peptidases {#sec3}
====================================

The accumulation of A*β* in the brain is one of the main symptoms of AD \[[@B3]\]. An abnormality in the proteolytic degradation of A*β* appears to be associated with the progression of AD \[[@B27]\]. As shown in [Figure 1](#fig1){ref-type="fig"}, several proteases that degrade A*β* in mice include insulin-degrading enzyme (IDE), neprilysin (NEP), and endothelin-converting enzyme (ECE) 1 and 2 \[[@B29], [@B28]\]. IDE (insulysin) is a \~110 KDa thiol zinc-metalloendopeptidase which is expressed in the cytosol, peroxisomes, and endosomes and on cell surfaces, and it is the major enzyme responsible for insulin degradation *in vitro* \[[@B30]\]. However, IDE has also been found to degrade A*β* in neuronal and microglial cells \[[@B31]\] and to eliminate the neurotoxic effects of A*β* \[[@B32]\]. Consistently, IDE-null mice showed increased levels of A*β* in the brain \[[@B33]\]. NEP is another key player in A*β* clearance \[[@B34]\]. In the brain, NEP is mainly expressed on neuronal plasma membranes \[[@B35]\]. NEP-null mice show defects in both the degradation of exogenously administered A*β* and in the metabolic suppression of endogenous A*β* levels in a gene dose-dependent manner \[[@B36]\]. The importance of these zinc-metalloendopeptidases in A*β* clearance is demonstrated by the fact that the transgenic overexpression of IDE or NEP in neurons significantly reduces A*β* levels and plaque associated with AD pathology \[[@B37]\]. Angiotensin-converting enzyme (ACE) is a membrane-bound zinc metalloprotease \[[@B38]\]. ACE mainly converts angiotensin I to angiotensin II, which is critical in the regulation of blood pressure, body fluid, and sodium homeostasis \[[@B39]\]. Recent studies indicate that ACE expression also promotes the degradation of A*β* \[[@B40]\].

Several receptor-mediated A*β* clearance mechanisms have already been examined \[[@B41]\]. Low-density lipoprotein receptor-related protein (LRP) and the receptor for advanced glycation end products (RAGE) regulate A*β* levels across the blood-brain barrier \[[@B42]\]. Both LRP and RAGE are multiligand cell surface receptors that mediate the clearance of a large number of proteins in addition to A*β*. LRP mainly removes A*β* from the brain to the periphery whereas RAGE appears to influx A*β* back to the brain from the periphery \[[@B41], [@B42]\].

4. Endothelin-Converting Enzymes (ECEs) {#sec4}
=======================================

ECEs are a class of type II transmembrane metalloproteases, which convert pro-ET into endothelin \[[@B43]\]. Two different ECEs, including ECE-1 and ECE-2, are expressed in brain regions related to AD \[[@B44], [@B45]\]. Although ECE-1 is abundantly expressed in vascular endothelial cells \[[@B46]\], it is also expressed in nonvascular cells, including hippocampal and neocortical pyramidal neurons, cerebellar Purkinje cells, and astrocytes \[[@B47]\]. ECE-2 is also expressed in the brain, especially in several subpopulations of neurons in the thalamus, hypothalamus, amygdala, and hippocampus \[[@B45]\]. Studies have demonstrated that ECE-1 is a key enzyme for the degradation of A*β* in the brain \[[@B48]\]. The *in vivo* function of ECE has been examined in ECE-1 heterozygous (+/−) and ECE-2 null (−/−) mice. In both cases, levels of A*β* were increased compared with wild-type mice, suggesting that these ECEs are an important A*β*-degrading enzyme *in vivo*\[[@B49]\]. Another study demonstrated that NEP (−/−)/ECE-1 (+/−) or NEP (−/−)/ECE-2 (−/−) mice have increased accumulation of both A*β*1--40 and A*β*1--42 in the brain \[[@B50]\]. Interestingly, a genetic variant of human ECE-1 (ECE1B C-338A) with increased promoter activity was associated with a reduced risk of sporadic AD in a French Caucasian population \[[@B44]\]. ECE-1 degrades synthetic A*β* levels *in vitro*\[[@B49]\] and is the main ECE for A*β* degradation. Recently, the expression of ECE-2 has also been shown to be a relevant A*β*-degrading enzyme and is dramatically increased at both mRNA and protein levels of patients with AD \[[@B51]\].

Endothelin-1 (ET-1) is the major peptide formed by ECE-1, and its cellular actions are mediated via two G-protein coupled receptors, ET~A~ and ET~B~, which are widely distributed in the brain \[[@B52]\]. ET-1 levels appear elevated in postmortem brains from patients with Alzheimer-type dementia \[[@B53]\]. A study indicates that ET-1 is increased in brain microvessels isolated from patients with AD and promotes the survival of brain neurons \[[@B54]\]. However, this effect might be associated with the protective actions of ET-1 *in vivo*, rather than contributing to the AD pathology \[[@B55]\].

5. PKC***ε***, MAPK, and ETS Pathways {#sec5}
=====================================

The activation of PKCs has suggested a neuroprotective function in animals \[[@B56]\]. PKC activators can also prevent the production of A*β* and extend the survival of AD transgenic mice \[[@B57]\]. However, chronic treatment of nonspecific PKC activators such as phorbol esters at high doses could increase levels of A*β* by decreasing PKC function or increasing APP synthesis \[[@B58]\]. These studies also suggest that the chronic application of phorbol esters may differentially regulate the function of PKC isoforms, downregulating PKC*α* and upregulating PKC*ε*. There are several mechanisms by which the activation of PKCs could regulate the reduction of A*β*. Interestingly, our recent study demonstrates that overexpression of human PKC*ε* reduces A*β* levels significantly in the brain ([Figure 2](#fig2){ref-type="fig"}). As shown in [Figure 3](#fig3){ref-type="fig"}, activation of PKCs including PKC*α* is known to promote *α*-secretase activity \[[@B23], [@B59]\], while activation or overexpression of PKC*ε* stimulates A*β*-degrading activity of ECE-1, probably via MAPK-dependent Ets-1 pathway \[[@B14], [@B15]\]. MAPK is also known to activate *α*-secretase activity independently \[[@B60]\] or through PKC activation \[[@B61]--[@B63]\]. Since MAPK can activate Ets-1 and 2 \[[@B64]\], it is possible that PKC*ε*-mediated MAPK could control ETS pathways and thus regulate ECE expression in the brain. Additionally, ETS transcription factors play a key role in cell growth, differentiation, and survival \[[@B65]\]. ETS proteins form complexes and act synergistically with other transcription factor families such as PEA3 or AP-1 \[[@B66]\]. Ets-1 has been known to be involved in angiogenesis \[[@B67]\]. However, another research indicates that upregulation of Ets-2 is closely associated with AD neurodegenerative lesions in the brain \[[@B68]\].

6. Conclusion {#sec6}
=============

In Alzheimer\'s disease (AD), it has long been known that activated PKCs reduce A*β* levels in the brain. PKC is also suggested to be a functional biomarker of AD \[[@B69]\]. The steady-state level of A*β* depends on a balance between production and clearance. In addition to A*β* production, several researchers suggest that enzyme-mediated degradation of A*β* is also critical for the regulation of A*β* levels \[[@B70]\]. Especially, since PKC is a key modulator in A*β* production or clearance in the brain \[[@B15], [@B57], [@B71]\], regulation of PKC activity could be a useful treatment target for AD \[[@B14], [@B72], [@B73]\]. However, the functional relevance of each PKC isoform in regulating A*β* levels in AD remains to be studied. Moreover, while *α*-secretase-mediated cleavage of APP via PKC isoforms reduces amyloid, detailed mechanisms of how PKC isoforms activate the enzyme-degradation system await further investigation. Therefore, PKC isoform-specific ligands or viral-mediated overexpression of PKC isoform as well as specific shRNAs approaches may unveil detailed molecular bases that underlie PKC-regulated A*β* clearance.
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![Amyloid metabolism by secretases and A*β*-degradation enzymes (ECE-1, IDE, NEP). A*β*-degrading proteases play an important role in regulating A*β* levels via known cleavage sites (adapted from \[[@B1], [@B29], [@B74]\]).](IJAD2011-857368.001){#fig1}

![Overexpression of PKC*ε* reduces the amyloid plaque burden and inhibits A*β* accumulation in brain parenchyma. (a) Thioflavin S staining and anti-A*β* immunostaining revealed fewer plaques and A*β* immunoreactive deposits in the hippocampus and neocortex in APP~Ind~/PKC*ε*~Tg1~ mice than in APP~Ind~ mice. Scale bar: 200 *μ*m. Quantification of (b) thioflavin S staining and (c) A*β* deposits in hippocampus and cortex sections (adapted from \[[@B14]\]). \**P* \< .05 by two-tailed *t*-test.](IJAD2011-857368.002){#fig2}

![Schematic summary of role of PKC-MAPK-dependent A*β* production and clearance. PKC*α* upregulates *α*-secretase activity while PKC*ε* stimulates A*β*-degrading activity of ECE-1, probably via MAPK-dependent Ets-1 pathway. MAPK is also known to activate *α*-secretase activity independently or through PKC activation.](IJAD2011-857368.003){#fig3}
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